EV
EVT.XETRA Evotec SE
- Market cap
- EUR 549M
- P/E
- -
- P/B
- 0.76x
- ROE
- -50.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is EVT.XETRA undervalued?
Graham numberThe Graham number of Evotec SE cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Evotec SE fundamental analysis
No fundamental analysis for Evotec SE yet.
Evotec SE stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Evotec SE
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and…
Full company profileEvotec SE financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Evotec SE annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 165M | 258M | 375M | 446M | 501M | 618M | 751M | 781M | 797M | 788M | 600M |
| Gross Profit | 58.6M | 82.6M | 112M | 133M | 126M | 152M | 174M | 175M | 115M | 65.2M | -6.30M |
| Operating Income | 31.3M | 37.5M | 77.5M | 62.6M | 48.5M | 27.3M | 12.5M | -47.5M | -143M | -141M | -213M |
| EBITDA | 45.6M | 35.5M | 106M | 86.8M | 90.4M | 298M | -86.1M | 877K | -80.7M | -41.4M | -117M |
| Net Income | 27.5M | 24.3M | 84.2M | 38.2M | 6.28M | 216M | -176M | -83.9M | -196M | -104M | -337M |
| EPS | 0.21 | 0.17 | 0.57 | 0.25 | 0.04 | 1.30 | -0.99 | -0.47 | -1.11 | -0.58 | -1.90 |
| Balance Sheet | |||||||||||
| Total Assets | 351M | 667M | 772M | 1.18B | 1.46B | 2.24B | 2.26B | 2.25B | 1.91B | 1.78B | 1.57B |
| Total Liabilities | 137M | 336M | 347M | 704M | 738M | 857M | 1.07B | 1.13B | 960M | 965M | 908M |
| Shareholders' Equity | 213M | 331M | 424M | 477M | 724M | 1.38B | 1.19B | 1.12B | 953M | 814M | 666M |
| Cash & Short-term Investments | 128M | 102M | 150M | 322M | 492M | 858M | 730M | 604M | 397M | 476M | 466M |
| Total Debt | 28.8M | 190M | 114M | 463M | 492M | 513M | 507M | 626M | 463M | 448M | 476M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 67.4M | 10.8M | 156M | 42.2M | 44.7M | 122M | 203M | 36.4M | 18.2M | -9.44M | -220M |
| Capital Expenditure | 10.1M | 17.6M | 27.9M | 31.9M | 99.1M | 119M | 181M | 216M | 132M | 72.5M | 26.6M |
| Free Cash Flow | 57.2M | -6.76M | 128M | 10.3M | -54.4M | 3.29M | 21.8M | -180M | -114M | -82.0M | -247M |
| Ratios | |||||||||||
| ROE | 12.9% | 7.3% | 19.9% | 8.0% | 0.9% | 15.6% | -14.8% | -7.5% | -20.6% | -12.7% | -50.7% |
| ROA | 7.8% | 3.6% | 10.9% | 3.2% | 0.4% | 9.6% | -7.8% | -3.7% | -10.3% | -5.8% | -21.4% |
| Net Profit Margin | 16.7% | 9.4% | 22.4% | 8.5% | 1.3% | 34.9% | -23.4% | -10.7% | -24.6% | -13.1% | -56.2% |
| Debt to Equity | 0.14x | 0.57x | 0.27x | 0.97x | 0.68x | 0.37x | 0.43x | 0.56x | 0.49x | 0.55x | 0.71x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Evotec SE dividends
Evotec SE has not paid dividends in the last 9 fiscal years.
Last stock split: 2:1 on Aug 18, 2000.
Who owns Evotec SE
- Insiders 9.97%
- Institutions 52.46%
- Public & others 37.58%
- Shares outstanding 178M
- Free float 147M
Evotec SE company profile
- Company name
- Evotec SE
- Ticker
- EVT.XETRA
- ISIN
- DE0005664809
- Exchange
- XETRA Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 4,461
- Fiscal year end
- December
- Address
- Essener Bogen 7, Hamburg, Germany, 22419
- Phone
- 49 40 560 81 0
- Website
- evotec.com
About Evotec SE
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions. The company collaborate with Odyssey Therapeutics, Inc. to designs and develops AI based discovery platform to discover new treatments in autoimmune and inflammatory diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Evotec SE management
10- Dr. Christian Wojczewski Ph.D.CEO & Chairperson of the Management Board · born 1973
- Ms. Aurelie DalbiezChief People Officer & Member of Management Board · born 1977
- Ms. Claire HinshelwoodCFO & Member of Management Board
- Dr. Ingrid MllerCOO & Member of Management Board · born 1972
- Dr. Sarah FakihExecutive VP, Head of Global Communications & Investor Relations
- Dr. Christian DargelEVP Global Head of Legal & Compliance · born 1971
- Dr. Ian M. HunneyballSenior Vice President of Programme Management & Clinical Operations · born 1950
- Dr. David HalletExecutive Vice President
- Uwe AndagEVP Head of Metabolic Diseases
- Ms. Christiane HonischSVP Head of Diagnostics